Idelalisib: all 47 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingNCT07218341Phase 4
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
• Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular LymphomaTerminatedNCT03890289Phase 2Results posted
• Pembrolizumab + Idelalisib for Lung Cancer StudyTerminatedNCT03257722Phase 1/2Results posted
• Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived MalignanciesTerminatedNCT03151057Phase 1Results posted
• 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell TransplantationCompletedNCT03133221Phase 2Results posted
• Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820TerminatedNCT02739360Phase 4Results posted
• Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKiCompletedNCT02639910Phase 2Results posted
• Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) AmyloidosisTerminatedNCT02590588Phase 2Results posted
• Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic LeukemiaTerminatedNCT02538614Phase 1Results posted
• Dose Optimization Study of Idelalisib in Follicular LymphomaTerminatedNCT02536300Phase 3Results posted
• Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström MacroglobulinemiaTerminatedNCT02439138Phase 2Results posted
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed DiseaseTerminatedNCT02436135Phase 1Results posted
• Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT02332980Phase 2Results posted
• Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic LymphomaTerminatedNCT02258529Phase 2Results posted
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT02242045Phase 1Results posted
• A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLCompletedNCT02135133Phase 2Results posted
• Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p DeletionTerminatedNCT02044822Phase 2Results posted
• Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic LeukemiaTerminatedNCT01980888Phase 3Results posted
• Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic LeukemiaTerminatedNCT01980875Phase 3Results posted
• Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic MalignanciesTerminatedNCT01796470Phase 2Results posted
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasTerminatedNCT01732926Phase 3Results posted
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasTerminatedNCT01732913Phase 3Results posted
• Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT01659021Phase 3Results posted
• Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
• Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )CompletedNCT01569295Phase 3Results posted
• A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)CompletedNCT01539512Phase 3Results posted
• Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)TerminatedNCT01539291Phase 3Results posted
• Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin LymphomaCompletedNCT01393106Phase 2Results posted
• Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade LymphomaCompletedNCT01306643Phase 1/2Results posted
• Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin LymphomasCompletedNCT01282424Phase 2Results posted
• A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLLTerminatedNCT01203930Phase 2Results posted
• An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib StudyTerminatedNCT01090414Phase 1/2Results posted
• A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisActive, not recruitingNCT06736990Phase 2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT03742323Phase 1/2
• Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell LymphomaCompletedNCT03576443Phase 2
• Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsWithdrawnNCT03349346Phase 1
• Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's MacroglobulinemiaCompletedNCT02962401Phase 2
• Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell TransplantWithdrawnNCT02662296Phase 2
• Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCLCompletedNCT02603445Phase 1
• Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)CompletedNCT02445131Phase 2
• Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT01838434Phase 1
• A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic LeukemiaWithdrawnNCT01659047Phase 2
• Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular LymphomaCompletedNCT01644799Phase 1
• Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental ChamberCompletedNCT00836914Phase 1
• Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic MalignanciesCompletedNCT00710528Phase 1

← Idelalisib overview